Reports Q3 revenue $102.69M, consensus $ $114.26M. “We are encouraged by the strong launch of RELYVRIO over the last year. We remain confident in the design and execution of our Phase 3 PHOENIX trial and now expect topline data in the second quarter of 2024,” said Joshua Cohen and Justin Klee, co-CEOs of Amylyx. “We are incredibly pleased with the rapid adoption of RELYVRIO at major ALS centers and focused on the work that we still need to do to reach more people living with ALS as we work towards our goal of transforming the way that ALS is treated.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMLX:
- Amylyx price target lowered to $46 from $48 at Mizuho
- Amylyx announces CHMP opinion on AMX0035 MAA
- Amylyx publishes ITT survival analysis of Centaur to historical control
- Mizuho expects news this week from Europe on Amylyx’s Relyvrio
- Amylyx provides update on Compassionate Access for AMX0035 in France